Search
Mexazolam
go.drugbank.com/drugs/DB15489InvestigationalMexazolam (CS-386) is a benzodiazepine indicated for the treatment of anxiety with or without psychoneurotic conditions. Mexazolam's structure is similar to that of other benzodiazepines such as oxazolam and cloxazolam. The use of benzod...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFennel
go.drugbank.com/drugs/DB15615ApprovedCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2E1 InhibitorsUlotaront
go.drugbank.com/drugs/DB15665InvestigationalSEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–assoc...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesEthyl biscoumacetate
go.drugbank.com/drugs/DB08794ApprovedWithdrawnEthyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBopindolol
go.drugbank.com/drugs/DB08807ExperimentalBopindolol (INN) is an ester prodrug for the beta blocker pindolol.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the t...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIvacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIvacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesDeferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalDeferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesLomitapide
go.drugbank.com/drugs/DB08827ApprovedLomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). It was developed to address the significant unmet medical need i...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates